Denosumab for Prevention of Fractures in Postmenopausal Women with Osteoporosis
Steven R. Cummings(University of California, San Francisco), Claus Christiansen(VA Eastern Colorado Health Care System), José Zanchetta(Universidad del Salvador), Suresh Siddhanti(Amgen (United States)), Michael R. McClung(Bone Health and Osteoporosis Foundation), Holly Brenza Zoog(Amgen (United States)), Ian R. Reid(University of Auckland), Andrea Wang(Amgen (United States)), Richard Eastell(University of Sheffield), Štěpán Kutílek, Ethel S. Siris(Columbia University Irving Medical Center), Javier San Martín(Universidad Nacional de Educación a Distancia), Silvano Adami(University of Verona), Matt Austin(Amgen (United States)), Pierre Delmas(Université Claude Bernard Lyon 1), Cesar Libanati(Amgen (United States))
Cited by 3,435
Related Papers
The diagnosis of osteoporosis
|Journal of Bone and Mineral Research|1994|3.9k
Variant of transcription factor 7-like 2 (TCF7L2) gene confers risk of type 2 diabetes
|Nature Genetics|2006|2.3k
Effects of Raloxifene on Bone Mineral Density, Serum Cholesterol Concentrations, and Uterine Endometrium in Postmenopausal Women
|New England Journal of Medicine|1997|1.6k
The clinician’s guide to prevention and treatment of osteoporosis
|Osteoporosis International|2022|1.3k
Effects of Oral Ibandronate Administered Daily or Intermittently on Fracture Risk in Postmenopausal Osteoporosis
|Journal of Bone and Mineral Research|2004|1.2k